Showing 2601-2610 of 18628 results for "".
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
https://reachmd.com/programs/cme/applying-the-evidence-tgct-treatment-insights-for-sports-medicine-physicians/48909/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
https://reachmd.com/programs/cme/the-safety-equation-managing-adverse-events-associated-with-csf1r-inhibitors-in-tgct/48910/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Building Blocks to Better IBD Veteran Patient Care: The APP Perspective
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/building-blocks-better-ibd-veteran-patient-care-app-perspective/17883/A multi-disciplinary approach to the care of Veteran patients through their IBD journey is crucial to appropriate treatment methods and maximized patient outcomes. In this session, we aim to discuss how healthcare professionals can work together to deliver excellent, all-inclusive care for IBD VeAll Sides of the Joint: Integrated TGCT Care Across Specialties
https://reachmd.com/programs/cme/all-sides-of-the-joint-integrated-tgct-care-across-specialties/48912/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
https://reachmd.com/programs/cme/emerging-evidence-in-focus-interpreting-data-on-next-generation-csf1r-tkis/48908/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Investigator Interview: Treating Rapidly Progressing Patients with ADPKD
https://reachmd.com/cme/nephrology/investigator-interview-treating-rapidly-progressing-patients-with-adpkd/12850/Investigator Interview: Treating Rapidly Progressing Patients with ADPKDEarlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
https://reachmd.com/programs/cme/earlier-action-lasting-impact-closing-the-ldl-c-gap-in-patients-without-a-prior-mace/39957/Experts review strategies for aggressive LDL lowering in high-risk patients without prior MI or stroke, highlighting updated targets and VESALIUS-CV data.Risk Stratification and Patient Selection for Perioperative ICIs
https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
https://reachmd.com/programs/cme/clinical-evidence-in-focus-interpreting-data-on-systemic-therapy-targeting-csf1r/48906/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
https://reachmd.com/clinical-practice/cardiology/global-burden-of-stroke-and-myocardial-infarction-in-patients-at-high-risk-of-first-mace-insights-from-the-vesalius-real-study/39990/Examine global rates of stroke and MI in patients at high-risk of first MACE without prior events, as explored in the VESALIUS-REAL burden of disease study.